May 6 (Reuters) – Eli Lilly said on Wednesday it would invest an additional $4.5 billion across two of its three sites in Indiana, bringing the U.S. drugmaker’s total capital expansion commitments in the state since 2020 to more than $21 billion.
The latest commitment would expand the company’s production capacity for genetic medicines and oral weight-loss drugs, after receiving U.S. market approval for its obesity pill Foundayo.
Lilly said the investment would incorporate new process designs and technologies at one of its future active pharmaceutical ingredient sites and at its first dedicated genetic medicine manufacturing facility.
The company’s U.S. capital expansion commitments since 2020 total more than $50 billion. It plans to break ground on several of its recently announced U.S. manufacturing sites this year.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
